Christopher E Barbieri

List of Publications by Year
in descending order

97 papers	9,829 citations	101543 36 h-index	42399 92 g-index
104 all docs	104 docs citations	104 times ranked	13534 citing authors

#	Article	IF	Citations
1	Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI Insight, 2022, 7, .	5.0	6
2	A multidisciplinary approach to optimize primary prostate cancer biobanking. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 271.e1-271.e7.	1.6	2
3	Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. , 2022, 1, .		23
4	Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. Nature Biotechnology, 2022, 40, 1488-1499.	17.5	46
5	Patient injuries and malfunctions associated with robotic prostatectomy: review of the manufacturer and user facility device experience database. Journal of Robotic Surgery, 2021, 15, 179-185.	1.8	4
6	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	17
7	Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer. Frontiers in Oncology, 2021, 11, 676716.	2.8	14
8	Tumor size and genomic risk in localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 434.e17-434.e22.	1.6	3
9	Editorial Comment. Journal of Urology, 2021, 206, 1155-1156.	0.4	0
10	Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell Reports, 2021, 36, 109625.	6.4	22
11	Active Surveillance for Men with Intermediate Risk Prostate Cancer. Journal of Urology, 2021, 205, 115-121.	0.4	12
12	Race and Genetic Alterations in Prostate Cancer. JCO Precision Oncology, 2021, 5, 1650-1653.	3.0	12
13	G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nature Communications, 2021, 12, 6662.	12.8	17
14	Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1Î±-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Translational Oncology, 2020, 13, 177-185.	3.7	22
15	Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. JAMA Network Open, 2020, 3, e2014674.	5.9	18
16	Diversity in Androgen Receptor Action Among Treatment-naÃ¯ve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. European Urology Open Science, 2020, 22, 34-44.	0.4	7
17	CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?. European Urology, 2020, 78, 680-681.	1.9	2
18	Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 418-422.	1.6	8

#	Article	IF	Citations
19	Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. JAMA Network Open, 2020, 3, e1920471.	5.9	61
20	Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nature Communications, 2020, 11, 1987.	12.8	29
21	Editorial Comment. Journal of Urology, 2020, 204, 712-713.	0.4	0
22	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16987-16996.	7.1	14
23	The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation. Nature Immunology, 2019, 20, 1196-1207.	14.5	42
24	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
25	Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility. European Urology, 2019, 76, 24-26.	1.9	3
26	FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature, 2019, 571, 408-412.	27.8	163
27	Intraductal carcinoma of the prostate in the absence of highâ€grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. Journal of Pathology, 2019, 249, 79-89.	4.5	44
28	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell, 2019, 35, 603-617.e8.	16.8	70
29	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Molecular Cancer Research, 2019, 17, 446-456.	3.4	44
30	The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. Journal of Urology, 2019, 202, 96-101.	0.4	4
31	N-Mycâ€“mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. Journal of Clinical Investigation, 2019, 129, 3924-3940.	8.2	115
32	Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial.. Journal of Clinical Oncology, 2019, 37, TPS137-TPS137.	1.6	0
33	Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5073-5073.	1.6	0
34	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	21.4	601
35	The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. Urology, 2018, 111, 122-128.	1.0	138
36	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29

#	Article	IF	Citations
37	Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation Rates. Journal of Sexual Medicine, 2018, 15, 1653-1658.	0.6	3
38	Molecular Subtypes of Prostate Cancer. Current Oncology Reports, 2018, 20, 58.	4.0	77
39	Introduction to â€œMolecular drivers of prostate cancer development, progression, and resistance to therapyâ€• Urologic Oncology: Seminars and Original Investigations, 2018, 36, 367.	1.6	0
40	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research, 2018, 24, 5585-5593.	7.0	113
41	Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.. Journal of Clinical Oncology, 2018, 36, 5064-5064.	1.6	2
42	Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. Journal of Urology, 2017, 198, 42-49.	0.4	15
43	Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5Î±-reductase Inhibition. European Urology, 2017, 72, 499-506.	1.9	16
44	Accurate Estimation of Prostate Size in the Evaluation of Nocturia. Current Bladder Dysfunction Reports, 2017, 12, 113-117.	0.5	0
45	SPOP Mutation Drives Prostate Tumorigenesis InÂVivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell, 2017, 31, 436-451.	16.8	152
46	Vasectomy and Risk of Prostate Cancer in a Screening Trial. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1653-1659.	2.5	9
47	Prostate cancerâ€“associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	30.7	240
48	Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial. Journal of Urology, 2017, 197, 1014-1019.	0.4	20
49	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	1.9	62
50	DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology, 2017, 71, 417-425.	1.9	169
51	Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. BJU International, 2017, 119, 298-304.	2.5	15
52	Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Journal of Translational Medicine, 2017, 15, 175.	4.4	5
53	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. Journal of Clinical Investigation, 2017, 128, 381-386.	8.2	29
54	Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. Journal of Urology, 2016, 196, 1047-1052.	0.4	49

#	Article	IF	Citations
55	Lethal Prostate Cancer in the PLCO Cancer Screening Trial. European Urology, 2016, 70, 2-5.	1.9	9
56	Editorial Comment. Journal of Urology, 2016, 196, 1444-1444.	0.4	0
57	Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia. European Urology, 2016, 69, 831-833.	1.9	8
58	Molecular subtyping of prostate cancer. Current Opinion in Urology, 2016, 26, 213-218.	1.8	40
59	Clinical variability and molecular heterogeneity in prostate cancer. Asian Journal of Andrology, 2016, 18, 543.	1.6	85
60	SPOP mutation leads to genomic instability in prostate cancer. ELife, 2015, 4, .	6.0	148
61	Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting. Prostate, 2015, 75, 337-347.	2.3	12
62	National Trends and Cost of Minimally Invasive Surgery in Urology. Urology Practice, 2015, 2, 49-54.	0.5	11
63	Reprint of: The prostate cancer genome: Perspectives and potential. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 95-102.	1.6	7
64	Genomic rearrangements in prostate cancer. Current Opinion in Urology, 2015, 25, 71-76.	1.8	27
65	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
66	Efficacy of Prostate-Specific Antigen Screening. JAMA Oncology, 2015, 1, 984.	7.1	13
67	Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology, 2014, 15, 439.	8.8	80
68	Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men. Clinical Cancer Research, 2014, 20, 4925-4934.	7.0	137
69	Recurrent Prostate Cancer Genomic Alterations Predict Response to Brachytherapy Treatment. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 594-600.	2.5	31
70	Incidental Prostate Cancer in Transurethral Resection of the Prostate Specimens in the Modern Era. Advances in Urology, 2014, 2014, 1-4.	1.3	30
71	SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. Neoplasia, 2014, 16, 14-W10.	5.3	145
72	TMPRSS2:ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia. Journal of Clinical Oncology, 2014, 32, 206-211.	1.6	90

#	Article	IF	Citations
73	Molecular Characterization of Prostate Cancer Following Androgen Deprivation: The Devil in the Details. European Urology, 2014, 66, 40-41.	1.9	4
74	The prostate cancer genome: Perspectives and potential. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 53.e15-53.e22.	1.6	58
75	The Lethal Clone in Prostate Cancer: Redefining the Index. European Urology, 2014, 66, 395-397.	1.9	30
76	The Mutational Landscape of Prostate Cancer. European Urology, 2013, 64, 567-576.	1.9	203
77	Evolution of Novel Biomarkers for Detection of Prostate Cancer. Journal of Urology, 2013, 190, 1970-1971.	0.4	11
78	Punctuated Evolution of Prostate Cancer Genomes. Cell, 2013, 153, 666-677.	28.9	1,107
79	Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456. Journal of Pathology, 2013, 231, 271-271.	4.5	1
80	Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6997-7002.	7.1	210
81	Next-generation Prostate Cancer Biobanking. Diagnostic Molecular Pathology, 2012, 21, 61-68.	2.1	31
82	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics, 2012, 44, 685-689.	21.4	1,300
83	Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology, 2012, 60, 187-198.	2.9	52
84	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. BJU International, 2012, 109, 685-690.	2.5	30
85	Deletion or underexpression of the Y-chromosome genes CDY2 and HSFY is associated with maturation arrest in American men with nonobstructive azoospermia. Asian Journal of Andrology, 2012, 14, 676-682.	1.6	28
86	Soluble gp130 Regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner. Journal of Urology, 2011, 186, 2107-2114.	0.4	15
87	Ureteroileal Anastomosis With Intraluminal Visualization: Technique and Outcomes. Urology, 2010, 76, 1496-1500.	1.0	5
88	Î”Np63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Developmental Biology, 2009, 329, 130-139.	2.0	12
89	Association of Procedure Volume With Radical Cystectomy Outcomes in a Nationwide Database. Journal of Urology, 2007, 178, 1418-1422.	0.4	106
90	p63 and epithelial biology. Experimental Cell Research, 2006, 312, 695-706.	2.6	119

#	Article	IF	Citations
91	The DNA Binding Activity of p53 Displays Reaction-Diffusion Kinetics. Biophysical Journal, 2006, 91, 330-342.	0.5	70
92	Loss of p63 Leads to Increased Cell Migration and Up-regulation of Genes Involved in Invasion and Metastasis. Cancer Research, 2006, 66, 7589-7597.	0.9	230
93	IGFBP-3 Is a Direct Target of Transcriptional Regulation by Î”Np63Î± in Squamous Epithelium. Cancer Research, 2005, 65, 2314-2320.	0.9	74
94	Ultraviolet Radiation Induces Phosphorylation and Ubiquitin-Mediated Degradation of ΔNP63α. Cell Cycle, 2005, 4, 710-716.	2.6	76
95	p53 family members: Similar biochemistry, Different biology. Cancer Biology and Therapy, 2005, 4, 425-426.	3.4	4
96	Inhibition of Epidermal Growth Factor Receptor Signaling Decreases p63 Expression in Head and Neck Squamous Carcinoma Cells. Laryngoscope, 2003, 113, 936-939.	2.0	46
97	Î”Np63Î± Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway. Journal of Biological Chemistry, 2003, 278, 51408-51414.	3.4	69